SCHEMBL6317115

SCHEMBL6317115

COc1ccc(OC)c(C(=O)C2CCC(OC)CC2c2ccc(N(C)C)c(OOP(=O)(O)O)c2)c1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.35
LMNA P02545 2/20 0.35
KDM4E B2RXH2 2/20 0.35
KDM1A O60341 2/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
APP P05067 1/20 0.33
HTT P42858 2/20 0.32
NPSR1 Q6W5P4 1/20 0.32
TUBB1 Q9H4B7 1/20 0.32
GRIK1 P39086 1/20 0.32
GRIA2 P42262 1/20 0.32
ALDH1A1 P00352 3/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32
ALOX15 P16050 1/20 0.31
NPC1 O15118 1/20 0.31
RAB9A P51151 1/20 0.31
POLB P06746 1/20 0.31
DDB1 Q16531 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6316492 0.95 MAPT (0.35) MAPTLMNAKDM4EKDM1AL3MBTL1
SCHEMBL6316373 0.92 MAPT (0.37) MAPTLMNAKDM4EKDM1AL3MBTL1
SCHEMBL6315215 0.92 MAPT (0.39) MAPTLMNAKDM4EKDM1AL3MBTL1
SCHEMBL6315408 0.91 MAPT (0.38) MAPTLMNAKDM4EKDM1AL3MBTL1
SCHEMBL6321011 0.89 MAPT (0.36) MAPTLMNAKDM4EKDM1AL3MBTL1
SCHEMBL6314117 0.89 KDM1A (0.37) MAPTLMNAKDM4EKDM1AHTT
SCHEMBL6316240 0.89 LMNA (0.36) MAPTLMNAKDM4EKDM1AL3MBTL1
SCHEMBL6315331 0.86 MAPT (0.38) MAPTLMNAKDM4EKDM1AL3MBTL1
SCHEMBL7125634 0.85 MAPT (0.41) MAPTLMNAKDM4EKDM1AL3MBTL1
SCHEMBL6315899 0.84 TUBB4A (0.35) MAPTLMNAKDM4EAPPTUBB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6887904-B2 Substituted arylcycloalkanes, compositions containing them and use thereof AVENTIS PHARMA S. A. (FR) 2005-05-03 US disclosed
US-20030149072-A1 Substituted arylcycloalkanes, compositions containing them and use thereof AVENTIS PHARMA S.A. (FR) 2003-08-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030149072-A1 Substituted arylcycloalkanes, compositions containing them and use thereof ABL1, MCL1, AHR MAPT 4538/4885LMNA 3280/4885KDM4E 1243/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.